Burka J F
Can J Physiol Pharmacol. 1987 Mar;65(3):442-7. doi: 10.1139/y87-075.
The lack of therapeutic efficacy of antihistaminic drugs in the treatment of asthma has led to the search and discovery of other bronchoconstrictor agents, particularly leukotrienes, thromboxanes, and platelet-activating factor. However, specific receptor antagonist for any of these substances have also not been particularly effective in inhibiting allergic bronchoconstriction. It is now generally accepted that histamine, arachidonic acid metabolites, platelet-activating factor, and possibly other substances are all involved to varying degrees in asthma and may indeed interact. This paper reviews the interaction of these mediators and how they contribute to airway hyperreactivity.
抗组胺药物在治疗哮喘方面缺乏疗效,这促使人们寻找和发现其他支气管收缩剂,尤其是白三烯、血栓素和血小板活化因子。然而,针对这些物质中任何一种的特异性受体拮抗剂在抑制过敏性支气管收缩方面也并非特别有效。现在人们普遍认为,组胺、花生四烯酸代谢产物、血小板活化因子以及可能的其他物质在哮喘中均有不同程度的参与,而且它们之间可能确实存在相互作用。本文综述了这些介质之间的相互作用以及它们如何导致气道高反应性。